The Cancer Immunotherapy Market Report is Segmented by Therapy Type (Monoclonal Antibodies, Immunomodulators, and More), Cancer Type (Prostate Cancer, Breast Cancer, Lung Cancer, and More), End Users (Hospitals and Clinics, Cancer Research Centers, and More), Route of Administration (Intravenous and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Cancer Immunotherapy Market is estimated to be valued at USD 158.42 Bn in 2025 and is expected to expand at CAGR of 12.3%, reaching USD 357.07 Bn by 2032.

This statistic depicts the global cancer immunotherapy market in 2023 and a projection for 2031, in billion U.S. dollars. In 2023, the market was estimated to be worth some 84 billion U.S. dollars. The market is expected to increase rapidly up to over 230 billion dollars by 2031.

Get key insights on Market Research Intellect's Cancer Immunotherapy Market Report: valued at USD 134.2 billion in 2024, set to grow steadily to USD 246.6 billion by 2033, recording a CAGR of 7.5%.Examine opportunities driven by end-user demand, R&D progress, and competitive strategies.

BCC Research Report: Dive into Cancer Immunotherapy market report analyzes the market trends of high-throughput screening with data from 2023 estimates from 2024 projections of CAGR through 2029.

The global cancer immunotherapy market is anticipated to reach $170.70 billion by 2028.BIS Research offers deep market insight, trends & forecast to 2028.

Check Market Research Intellect's Cancer Immunotherapy Market Report, pegged at USD 120 billion in 2024 and projected to reach USD 250 billion by 2033, advancing with a CAGR of 9.5% (2026-2033).Explore factors such as rising applications, technological shifts, and industry leaders.

Cancer Immunotherapy Market size was valued at around USD 134.4 billion in 2024 and is projected to reach USD 214.7 billion by 2030, growing at 8.12% CAGR (2025-30).

Snapshot img

Cancer Immunotherapy Market Size 2024-2028

The cancer immunotherapy market size is valued to increase USD 45.5 billion, at a CAGR of 8.1% from 2023 to 2028. High prevalence of cancer will drive the cancer immunotherapy market.

Major Market Trends & Insights

North America dominated the market and accounted for a 43% growth during the forecast period.
By Type - Monoclonal antibodies segment was valued at USD 36.30 billion in 2022
By Application - Lung cancer segment accounted for the largest market revenue share in 2022

Market Size & Forecast

Market Opportunities: USD 99.29 billion
Market Future Opportunities: USD 45.50 billion
CAGR from 2023 to 2028 : 8.1%

Market Summary

The market represents a significant and rapidly evolving sector in the healthcare industry. This market is characterized by the adoption of advanced core technologies, including immune checkpoint inhibitors, CAR-T cell therapy, and monoclonal antibodies, which are transforming cancer treatment. Applications span various types of cancer, with a high prevalence in lung, breast, and skin cancers. Service types or product categories include biopharmaceutical companies, research institutions, and hospitals. Regulations play a crucial role, with stringent policies ensuring safety and efficacy. For instance, the US Food and Drug Administration (FDA) has approved over 20 immunotherapies since 2011. Despite challenges, such as high costs and limited accessibility, opportunities abound, including the development of combination therapies and personalized medicine. According to a recent study, the global immunotherapy market is expected to reach a 30% market share in the oncology therapeutics market by 2027.

What will be the Size of the Cancer Immunotherapy Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Cancer Immunotherapy Market Segmented ?

The cancer immunotherapy industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. TypeMonoclonal antibodiesCheck point inhibitors and immunomodulatorsCancer vaccinesApplicationLung cancerBreast cancerColorectal cancerOthersGeographyNorth AmericaUSCanadaEuropeFranceGermanyAPACChinaRest of World (ROW)

By Type Insights

The monoclonal antibodies segment is estimated to witness significant growth during the forecast period.

The market continues to evolve, driven by advancements in immune cell engineering and tumor microenvironment understanding. Personalized immunotherapies, such as adoptive cell transfer and cancer cell destruction, are revolutionizing treatment. Patient response prediction relies on immunomodulatory antibodies, immunogenicity assays, and treatment response biomarkers. Progression-free survival rates have improved with oncolytic viruses, t cell activation, and cytokine therapy. Monoclonal antibodies, targeting the major histocompatibility complex, are integral to immune system stimulation, with clinical trial outcomes showing promising overall survival rates. Novel approaches include antibody-drug conjugates, cancer vaccines, and combination therapies using chimeric antigen receptors, checkpoint blockade, neoantigen targeting, and dendritic cell vaccines. Bispecific antibodies and tumor-associated antigens are also under investigation. Adverse event profiles are closely monitored to ensure safe and effective treatments. The market's continuous growth is a testament to the ongoing research and development in this field.

Request Free Sample

The Monoclonal antibodies segment was valued at USD 36.30 billion in 2018 and showed a gradual increase during the forecast period.

Request Free Sample

Regional Analysis

North America is estimated to contribute 43% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

See How Cancer Immunotherapy Market Demand is Rising in North America Request Free Sample

North America's the market holds the largest global share, primarily due to substantial investments in the oncology sector in the US. The US dominates this regional market, contributing significantly to its revenue generation. The pharmaceutical industry's considerable investments, particularly in the oncology sector, and the presence of leading pharmaceutical companies in the region underpin the US's market dominance. In the US, cancer remains one of the most prevalent chronic diseases, with approximately 436 new cases reported per 100,000 population and about 156 deaths in the same year.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with

The statistic shows the global cancer immunotherapy market in 2017, distributed by world region. In that year, North America was reported to have a market share of almost 45 percent within the global cancer immunotherapy market.

Explore insights from Market Research Intellect's Cancer Immunotherapy Market Report, valued at $107.5 billion in 2024, expected to reach $201.4 billion by 2033 with a CAGR of 8.0% during 2026-2033.Uncover opportunities across demand patterns, technological innovations, and market leaders.

The global Cancer Immunotherapy Market was valued at USD 128.74 Billion in 2023 and is projected to reach USD 238.38 Billion by 2030, registering a CAGR of 9.2% for the forecast period 2024-2030. The key driving factors for the Cancer Immunotherapy Market

The surging worldwide incidence of cancer, coupled with significant investments in the research and development of groundbreaking oncology therapies eventually drives the cancer immunotherapy market growth.

The global population continues to grow, and as people age, the risk of developing cancer increases. With more people living longer, there is a higher prevalence of cancer diagnoses. Modern lifestyles characterized by poor dietary habits, lack of physical activity, and increased exposure to environmental carcinogens have contributed to the rising incidence of cancer. Advances in medical imaging and diagnostic technologies have led to earlier and more accurate cancer detection, leading to an increase in reported cases. The use of tobacco and alcohol, known carcinogens, remains a significant contributor to cancer incidence, particularly in lung, liver, and oral cancers.

For instance, the Parker Institute for Cancer Immunotherapy has forged partnerships with researchers and industry experts to pioneer revolutionary immune-based cancer therapies. According to data from the Global Cancer Observatory, the United States recorded approximately 2,281,658 cancer diagnoses and 612,390 cancer-related fatalities in 2020. The prevalent malignancies impacting the U.S. populace encompass breast, prostate, lung, and colorectal cancers.
For instance, data from the Cancer Council reveals that Australia documented 150,000 new cancer diagnoses and 50,000 cancer-related fatalities in 2020. Consequently, the notable increase in the incidence of cancer cases is expected to propel market growth in the foreseeable future.
For instance, the Cancer Research Institute has provided funding for over 120 clinical trials and has allocated approximately USD 474 million towards research endeavors. Additionally, the Society for Immunotherapy of Cancer (SITC) is actively committed to enhancing patient outcomes by advancing the field of oncology immunotherapy. These organizations collaborate closely with scientists and researchers to explore innovative immune therapy treatment approaches.
For instance, In June 2022, a team of researchers at Stanford University secured a grant of USD 13 million from Cancer Grand Challenges, an initiative jointly supported by Cancer Research UK and the U.S. National Cancer Institute. This financial support has been granted to advance the development of cutting-edge immunotherapies, explore extrachromosomal DNA, and delve into the study of early-stage cancer

Expanding indications & personalized medicines significantly boost the cancer immunotherapy market growth.

Immunotherapies are being explored for a wide range of cancer types, including melanoma, lung cancer, bladder cancer, breast cancer, and more. As research uncovers new targets and mechanisms, the potential applications of immunotherapy continue to expand. Advances in understanding the genetic and molecular characteristics of tumors have led to the development of personalized immunotherapies. Tailoring treatments to an individual's unique tumor profile can improve response rates and reduce side effects. Thus, expanding indications & personalized medicines eventually boost the cancer immunotherapy market growth.

The Restraining Factor of Cancer Immunotherapy Market

Autoimmune reactions & skin reactions may restrain the cancer immunotherapy market growth.

Immunotherapies can trigger autoimmune reactions where the immune system mistakenly targets and damages normal cells or tissues, leading to conditions such as colitis, hepatitis, thyroiditis, and pneumonitis. Rashes, itching, and more severe skin conditions like dermatitis and bullous pemphigoid can occur as a result of immunotherapy. These several factors may hamper the cancer immunotherapy market growth.

Impact of the COVID-19 Pandemic on the Cancer Immunotherapy Market

Clinical trials are essential for testing the safety and efficacy of new cancer immunotherapies. The pandemic disrupted many clinical trials, leading to delays in drug development and regulatory approvals. These delays have affected the introduction of new treatments to the market. Shifts in Healthcare Resources: Hea...

The Cancer Immunotherapy Market size was valued at USD 138.87 billion in 2023 and is projected to reach USD 242.67 billion by 2032, exhibiting a CAGR of 8.3 % during the forecasts period. Recent developments include: In October 2023, Pfizer launched the MEKTOVI (binimetinib) + BRAFTOVI (encorafenib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test has received approval from U.S. Food and Drug Administration (FDA) , In October 2023, Merck's anti-PD-1 therapy KEYTRUDA was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable non-small cell lung cancer (NSCLC) as neoadjuvant treatment and adjuvant treatment following surgery , In December 2023, the xU.S. FDA approved the FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer by Takeda .

The Global Cancer Immunotherapy Market Size Was Worth USD 120.93 Billion in 2023 and Is Expected To Reach USD 412.28 Billion by 2032, CAGR of 14.60%.

Cancer Immunotherapy Market size was valued at USD 121696.34 Million in 2023 and is expected to reach USD 310458.68 Million in 2031, at a CAGR of 13.70% over the forecast period of 2024 to 2031.

Key Market Drivers • Rising Global Cancer Burden: The escalating incidence of cancer worldwide is a primary driver for the Cancer Immunotherapy Market. According to the WHO's GLOBOCAN 2022 database, approximately 19.3 million new cancer cases were reported in 2020, with this number projected to reach 28.4 million by 2040. The American Cancer Society reported that immunotherapy treatments were recommended for approximately 42% of all newly diagnosed cancer patients in 2023, up from 28% in 2020. • Improving Treatment Success Rates: Enhanced efficacy of immunotherapy treatments is driving market growth. The FDA reported that the response rate for checkpoint inhibitor immunotherapies increased from 26.5% in 2020 to 41.3% in 2023 across various cancer types. The American Society of Clinical Oncology (ASCO) documented that CAR T-cell therapy showed complete remission rates of 83% in specific blood cancers by 2023, compared to 67% in 2020.

Global Cancer Immunotherapy Market is segmented by Application (Lung Cancer_Melanoma_Breast Cancer_Prostate Cancer_Hematological Malignancies), Type (Immune Checkpoint Inhibitors_Monoclonal Antibodies_Cancer Vaccines_CAR T-Cell Therapy_Cytokine Therapy), and Geography (North America_ LATAM_ West Europe_Central & Eastern Europe_ Northern Europe_ Southern Europe_ East Asia_ Southeast Asia_ South Asia_ Central Asia_ Oceania_ MEA)

Cancer Immunotherapy Market Outlook

According to our latest research, the global cancer immunotherapy market size reached USD 138.1 billion in 2024, reflecting robust momentum driven by technological advancements and increasing cancer incidence worldwide. The market is expected to grow at a CAGR of 10.3% during the forecast period, reaching an estimated USD 334.7 billion by 2033. This significant growth is primarily attributed to the rising demand for targeted and personalized cancer treatments, ongoing developments in immunotherapy modalities, and heightened awareness about the efficacy of immunotherapeutic approaches in comparison to conventional therapies.

One of the primary growth factors fueling the expansion of the cancer immunotherapy market is the increasing prevalence of various cancer types globally. The World Health Organization (WHO) has consistently reported a rise in cancer incidence, with lifestyle changes, aging populations, and environmental factors contributing to this surge. As cancer becomes a leading cause of mortality, there is heightened urgency for effective and less invasive treatment options. Immunotherapy has emerged as a promising approach due to its ability to harness the body’s immune system to target and destroy cancer cells, thereby reducing the adverse effects often associated with traditional therapies like chemotherapy and radiation. This paradigm shift toward immunotherapeutic solutions is driving both clinical research and commercial investments in the sector.

Another crucial growth driver in the cancer immunotherapy market is the rapid pace of innovation and approvals of new therapies. The past decade has witnessed the introduction and regulatory approval of several breakthrough immunotherapy drugs, such as immune checkpoint inhibitors and CAR-T cell therapies. These advancements have not only improved survival rates for patients with previously hard-to-treat cancers but have also expanded the scope of immunotherapy to a wider range of malignancies. Pharmaceutical and biotechnology companies are heavily investing in research and development (R&D) to enhance the efficacy, safety, and applicability of immunotherapeutic agents, fostering a dynamic pipeline of candidate drugs and combination therapies that promise to further revolutionize cancer care.

Furthermore, the growing adoption of personalized medicine and biomarker-driven therapies is accelerating the uptake of cancer immunotherapy. The integration of genetic, molecular, and immunological profiling into clinical practice enables the identification of patients who are most likely to benefit from specific immunotherapies, thereby optimizing treatment outcomes and minimizing unnecessary side effects. This trend is supported by advancements in diagnostic technologies, such as next-generation sequencing and companion diagnostics, which facilitate precise patient stratification and monitoring. As healthcare systems and payers increasingly recognize the value of personalized immunotherapy, reimbursement frameworks are evolving to support broader patient access, further propelling market growth.

From a regional perspective, North America continues to dominate the cancer immunotherapy market, accounting for the largest share in 2024 due to its advanced healthcare infrastructure, high R&D expenditure, and early adoption of novel therapies. Europe follows closely, benefiting from strong regulatory support and collaborative research initiatives. The Asia Pacific region is emerging as a high-growth market, driven by rising cancer prevalence, improving healthcare access, and increasing investments in biotechnology. Latin America and the Middle East & Africa are also witnessing gradual market expansion, supported by growing awareness and government initiatives aimed at enhancing cancer care. Collectively, these regional trends underscore the global momentum in adopting immunotherapy as a cornerstone of modern oncology.

Therapy Type Analysis

The cancer immunotherapy market is segmented by therapy type into monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, adoptive cell transfer, cytokines, and others. Among these, monoclonal antibodies have historically held the largest market share due to their proven efficacy across multiple cancer types and established clinical track record. These biologic agents work by specifically targeting antigens present on cancer cells, thereby minimizing damage to healthy tissues and reducing systemic toxicity. The continued developmen

The global cancer immunotherapy market, valued at $137.71 billion in 2025, is projected to experience robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 10.45% from 2025 to 2033. This expansion is driven by several key factors. Firstly, the rising incidence of various cancer types globally fuels demand for effective treatment options. Secondly, advancements in immunotherapy technologies, such as the development of more targeted and efficacious monoclonal antibodies, immune checkpoint inhibitors, and cancer vaccines, are significantly contributing to market growth. The increasing understanding of the human immune system and its role in cancer progression is enabling the creation of novel therapies with improved safety profiles and efficacy. Furthermore, supportive government initiatives and increased research and development funding are fostering innovation and accelerating the commercialization of new immunotherapy treatments. Finally, the growing adoption of personalized medicine approaches, tailoring treatment strategies based on individual patient characteristics and tumor profiles, is further boosting market expansion. The market segmentation reveals significant opportunities across various therapy types, applications, and end-users. Monoclonal antibodies currently dominate the therapy type segment, however, immune checkpoint inhibitors and cancer vaccines are expected to witness substantial growth due to their promising clinical outcomes. In terms of application, lung, breast, and prostate cancers represent major market segments, reflecting their high prevalence. Hospitals and clinics constitute the largest end-user segment, although the growing involvement of cancer research centers in clinical trials and advanced therapies is likely to increase their market share over the forecast period. Geographically, North America and Europe currently hold the largest market share, driven by strong healthcare infrastructure, high disposable incomes, and early adoption of advanced therapies. However, rapidly growing economies in Asia-Pacific, particularly in China and India, are expected to drive substantial growth in this region over the next decade. Competition in the market is fierce, with key players such as Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, and Pfizer engaged in ongoing research and development activities, as well as strategic collaborations and acquisitions to consolidate their market positions. Recent developments include: In August 2024, AstraZeneca’s Imfinzi (durvalumab), an immunotherapy in combination with chemotherapy was approved in the United States for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements., In June 2024, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck), a type of immunotherapy that can be used with carboplatin and paclitaxel. This combination is followed by a regimen of single-agent pembrolizumab, specifically targeting adult patients suffering from primary advanced or recurrent endometrial carcinoma.. Key drivers for this market are: Rising R&D Activities, Increasing Effectivity and Accuracy Of Newer Therapies; Growing Prevalence of Cancer. Potential restraints include: Rising R&D Activities, Increasing Effectivity and Accuracy Of Newer Therapies; Growing Prevalence of Cancer. Notable trends are: Breast Cancer Segment Expected to Hold a Major Share in the Cancer Immunotherapy Market.

By 2035, the Cancer Immunotherapy Market is estimated to expand to USD 382.78 Billion, showcasing a robust CAGR of 10.72% between 2025 and 2035, starting from a valuation of USD 124.87 Billion in 2024 and USD 138.26 Billion in 2025.

In Europe Cancer Immunotherapy Market is projected to grow from USD 124.3 billion in 2025 to USD 261.8 billion by 2031, at a CAGR of 13.2%